In the past week, OTLK stock has gone down by -5.41%, with a monthly decline of -6.67% and a quarterly plunge of -1.41%. The volatility ratio for the week is 12.70%, and the volatility levels for the last 30 days are 8.92% for Outlook Therapeutics Inc The simple moving average for the past 20 days is -4.97% for OTLK’s stock, with a -70.16% simple moving average for the past 200 days.
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
OTLK has 36-month beta value of 0.43. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for OTLK is 20.52M, and currently, short sellers hold a 19.14% ratio of that float. The average trading volume of OTLK on March 28, 2025 was 762.82K shares.
OTLK) stock’s latest price update
The stock of Outlook Therapeutics Inc (NASDAQ: OTLK) has increased by 8.53 when compared to last closing price of 1.29.Despite this, the company has seen a loss of -5.41% in its stock price over the last five trading days. globenewswire.com reported 2025-02-28 that ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic product which, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).
Analysts’ Opinion of OTLK
BTIG Research, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $50. The rating they have provided for OTLK stocks is “Buy” according to the report published on March 27th, 2024.
Chardan Capital Markets gave a rating of “Buy” to OTLK, setting the target price at $3 in the report published on February 15th of the previous year.
OTLK Trading at -17.33% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.10% of loss for the given period.
Volatility was left at 8.92%, however, over the last 30 days, the volatility rate increased by 12.70%, as shares surge +1.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.19% lower at present.
During the last 5 trading sessions, OTLK fell by -5.41%, which changed the moving average for the period of 200-days by -79.38% in comparison to the 20-day moving average, which settled at $1.4733. In addition, Outlook Therapeutics Inc saw -25.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from KENYON LAWRENCE A, who purchase 5,000 shares at the price of $5.69 back on Sep 26 ’24. After this action, KENYON LAWRENCE A now owns 5,946 shares of Outlook Therapeutics Inc, valued at $28,446 using the latest closing price.
Haddadin Yezan Munther, the Director of Outlook Therapeutics Inc, purchase 1,882 shares at $11.82 during a trade that took place back on Mar 28 ’24, which means that Haddadin Yezan Munther is holding 5,049 shares at $22,242 based on the most recent closing price.
Stock Fundamentals for OTLK
The total capital return value is set at 0.0.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -353447.51.
Currently, EBITDA for the company is -71.59 million with net debt to EBITDA at 2.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.32.
Conclusion
To put it simply, Outlook Therapeutics Inc (OTLK) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
